Subtype
Invasive Prostate Carcinoma
CI-CAN-00002961Explore in graph →
139 active trials1 approved drugs3 evidence items
- NCIt
- C48596
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002961Explore in graph →
Clinical trials
440 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (72)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06205316 | SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma | active not recruiting | Phase 3 | 118 | Mayo ClinicOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT03070886 | Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery | active not recruiting | Phase 2 / Phase 3 | 612 | NRG OncologyOTHER | 3 | Sep 14, 2026 | clinicaltrials |
| NCT04134260 | Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial | active not recruiting | Phase 3 | 586 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT04513717 | Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial | active not recruiting | Phase 3 | 2,753 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06235151 | Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer(Solar-Stage) | active not recruiting | Phase 3 | 439 | Curium US LLCINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT04455750 | A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy(CASPAR) | active not recruiting | Phase 3 | 61 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03367702 | Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer | active not recruiting | Phase 3 | 692 | NRG OncologyOTHER | 6 | Jan 15, 2026 | clinicaltrials |
| NCT04446117 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC(CONTACT-02) | active not recruiting | Phase 3 | 575 | ExelixisINDUSTRY | 27 | Dec 18, 2025 | clinicaltrials |
| NCT01952223 | A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse(PEACE2) | active not recruiting | Phase 3 | 761 | UNICANCEROTHER | 1 | Jul 30, 2025 | clinicaltrials |
Data updated 12 days agoSource updated Sep 17, 2026source: clinicaltrials